SEATTLE–(BUSINESS WIRE)–#HeparinMarket–According to Coherent Market Insights, the global heparin market was
valued at US$ 9.4 billion in 2017, and is projected to exhibit a CAGR of
5.1% over the forecast period (2018 – 2026).
Key Trends and Analysis of the Heparin Market:
Market players are focusing on product approvals and launches, which is
expected to be a major factor for growth of global heparin market in the
near future. For instance, in December 2017, Mylan N.V., a
pharmaceutical company, received approval from the U.S. FDA for its
abbreviated new drug applications (ANDAs) for Heparin Sodium Injection
USP, 1,000 USP/mL, 5,000 USP/mL, 10,000 USP/mL, and 20,000 USP/mL, all
of which are packaged in multi-dose vials.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2602
Furthermore, in April, 2019, B. Braun Medical Inc. launched Heparin
Sodium Injection, USP – 5,000 USP Unit / 0.5 mL prefilled syringe. The
syringe is attached with safety needle for subcutaneous and intravenous
use in the U.S.
Furthermore, in June 2018, Amphastar Pharmaceuticals, Inc. received the
U.S. Food and Drug Administration (FDA) approval of the company’s
abbreviated new drug application (ANDA) supplement for semi-purified
heparin and Heparin sodium USP.
To know the latest trends and insights prevalent in this market,
click the link below:
Key Market Takeaways:
The global heparin market is expected to exhibit a CAGR of 5.1% during
the forecast period (2018–2026), attributed to rising cases of
conditions such as coronary heart disease, pulmonary embolism, and
deep vein thrombosis. Myocardial infarction (MI) is one of the major
complications of coronary heart disease.
According to the American Heart Association 2018 report, coronary
heart disease is the leading cause (43.8%) of deaths due to
cardiovascular disease in the U.S., followed by stroke (16.8%). As per
the Centers for Disease Control and Prevention (CDC) 2015 report, deep
vein thrombosis affected around 900,000 individuals in the U.S.
Asia Pacific heparin market is expected to grow at the highest rate
during the forecast period, owing to increasing incidence of
myocardial infarction (MI) among regional population. According to a
study published by National Center for Biotechnology Information
(NCBI) in 2015, Asian population is more susceptible to MI than white
people. There are 50% higher cases of MI in South Asians than in white
people in the U.K.
Key players operating in the global heparin market include Anselm
Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG,
Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE
& Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi
S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United
Biotech (P) Ltd.
Buy this report now @ https://www.coherentmarketinsights.com/insight/buy-now/2602
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting
firm offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave.
Email: [email protected]